Brian Geist
Overview
Explore the profile of Brian Geist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vazvaei-Smith F, Li W, Barnaby O, Bhardwaj S, Dong J, Dumont C, et al.
AAPS J
. 2025 Mar;
27(2):57.
PMID: 40069400
The analysis of Non-Liquid Matrices (NLMs) can provide key information on many aspects in drug discovery and development. These include but are not limited to drug uptake and distribution, engagement...
2.
Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K, et al.
iScience
. 2025 Mar;
28(3):111876.
PMID: 40060890
T cell-redirecting bispecific antibodies (bsAbs) to treat advanced stage solid tumors are gaining interest after recent clinical successes. The immune checkpoint human leukocyte antigen G (HLA-G) is expressed in several...
3.
Goldberg S, Satomaa T, Aina O, Aitio O, Burke K, Dudkin V, et al.
Mol Cancer Ther
. 2024 Feb;
23(11):1530-1543.
PMID: 38324296
Antibody-drug conjugates (ADC) have shown impressive clinical activity with approval of many agents in hematologic and solid tumors. However, challenges remain with both efficacy and safety of ADCs. This study...
4.
Zheng S, Polidori D, Wang Y, Geist B, Lin-Schmidt X, Furman J, et al.
Clin Transl Sci
. 2023 May;
16(8):1431-1444.
PMID: 37154518
Growth Differentiation Factor-15 (GDF15) is a circulating polypeptide linked to cellular stress and metabolic adaptation. GDF15's half-life is ~3 h and activates the glial cell line-derived neurotrophic factor family receptor...
5.
Edavettal S, Cejudo-Martin P, Dasgupta B, Yang D, Buschman M, Domingo D, et al.
Med
. 2022 Oct;
3(12):860-882.e15.
PMID: 36257298
Background: The near impermeability of the blood-brain barrier (BBB) and the unique neuroimmune environment of the CNS prevents the effective use of antibodies in neurological diseases. Delivery of biotherapeutics to...
6.
White I, Tamot N, Doddareddy R, Ho J, Jiao Q, Harvilla P, et al.
MAbs
. 2021 Oct;
13(1):1987180.
PMID: 34693867
The global health crisis and economic tolls of COVID-19 necessitate a panoply of strategies to treat SARS-CoV-2 infection. To date, few treatment options exist, although neutralizing antibodies against the spike...
7.
Ayyar V, Jaiprasart P, Geist B, Huang Devine Z, Case M, Hazra A, et al.
Br J Pharmacol
. 2021 May;
178(19):3943-3958.
PMID: 34008170
Background And Purpose: Antigen-binding fragment (F ) reversal agents were developed to reverse, in bleeding emergency, the long-acting anticoagulant effect of JNJ-64179375 (JNJ-9375), a monoclonal antibody that binds exosite-1 on...
8.
Zheng S, Niu J, Geist B, Fink D, Xu Z, Zhou H, et al.
MAbs
. 2020 Sep;
12(1):1813962.
PMID: 32967523
Biotherapeutic drugs against tumor necrosis factor (TNF) are effective treatments for moderate to severe inflammatory bowel disease (IBD). Here, we evaluated CNTO 5048, an antimurine TNF surrogate monoclonal antibody (mAb),...
9.
Zheng S, Shen F, Jones B, Fink D, Geist B, Nnane I, et al.
MAbs
. 2020 Jun;
12(1):1770018.
PMID: 32544369
Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). JNJ-61178104 is a novel...
10.
Vellalore Maruthachalam B, Zwolak A, Lin-Schmidt X, Keough E, Tamot N, Venkataramani S, et al.
MAbs
. 2020 Jan;
12(1):1708030.
PMID: 31906797
Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the...